SCHEMBL1427686

SCHEMBL1427686

CCN(CC)CCCNc1nc(NC2CCNCC2)c2ccccc2n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 3/20 0.58
▸ EHMT2 Q96KQ7 3/20 0.58
▸ RCOR1 Q9UKL0 2/20 0.56
▸ CXCR4 P61073 1/20 0.55
▸ POLB P06746 1/20 0.51
▸ CYP1A2 P05177 7/20 0.50
▸ LMNA P02545 4/20 0.50
▸ CYP3A4 P08684 3/20 0.50
▸ HSD17B10 Q99714 3/20 0.50
▸ TP53 P04637 2/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ CYP2D6 P10635 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ RECQL P46063 1/20 0.50
▸ BLM P54132 1/20 0.50
▸ HBB P68871 1/20 0.50
▸ TOP2A P11388 1/20 0.50
▸ TRIM58 Q8NG06 1/20 0.49
▸ CLK4 Q9HAZ1 4/20 0.49
▸ GAA P10253 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1427755 0.90 KDM1A (0.71) KDM1AEHMT2RCOR1CXCR4CYP1A2
SCHEMBL1428484 0.86 KDM1A (0.66) KDM1AEHMT2RCOR1CXCR4CYP1A2
SCHEMBL11861178 0.82 POLB (0.71) POLBTOP2ATRIM58GAACACNA2D1
SCHEMBL9911796 0.80 EHMT2 (0.66) KDM1AEHMT2RCOR1
SCHEMBL1427795 0.79 EHMT2 (0.67) KDM1AEHMT2RCOR1
SCHEMBL9912722 0.78 EHMT2 (0.63) KDM1AEHMT2RCOR1
SCHEMBL1430305 0.78 EHMT2 (0.63) KDM1AEHMT2RCOR1
SCHEMBL8890767 0.78 POLB (0.61) POLBTOP2ATRIM58GAACACNA2D1
SCHEMBL9911797 0.77 EHMT2 (0.64) KDM1AEHMT2RCOR1
SCHEMBL1427881 0.77 EHMT2 (0.61) KDM1AEHMT2RCOR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193203-B2 Bicyclic compounds having activity at the CXCR4 receptor ALLERGAN, INC. (US) 2012-06-05 — — US disclosed
EP-2300456-A1 BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR Allergan, Inc. (US) 2011-03-30 — — EP disclosed
US-20090312305-A1 BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR ALLERGAN, INC. (US) 2009-12-17 — — US disclosed
WO-2009143058-A1 BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR ALLERGAN, INC. (US) 2009-11-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312305-A1 BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR CXCR4, CXCR2, CXCL12 KDM1A 4804/4885EHMT2 4669/4885RCOR1 3069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback